Xenogeneic Immunization in mice using HER2 DNA delivered by an adenoviral vector

International Journal of Cancer

Volumn 113, Issue 1, 2005, Pages 67-77

  Gallo, Pasquale ^a   Dharmapuri, Sridhar ^a   Nuzzo, Maurizio ^a   Maldini, Daniele ^a   Iezzi, Manuela ^b   Cavallo, Federica ^c   Musiani, Piero ^b   Forni, Guido ^c   Monaci, Paolo ^a,d  

^a Ist Ric Biol Melecolare P A   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

^d IRBM   (Italy)

Author keywords

Adenovirus; Antitumor vaccination; Breast cancer; neu transgenic mice

Indexed keywords

ADENOVIRUS VECTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITOPE; GAMMA INTERFERON; N (4 METHOXYPHENYLACETYL)DEHYDROALANINE; N (4 METHOXYPHENYLACETYL)DEHYDROALANINE EPIDERMAL GROWTH FACTOR RECEPTOR 2; PLASMID DNA; PROTEIN P185; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CARCINOMA; CANCER INHIBITION; CARCINOGENESIS; CELLULAR IMMUNITY; CONTROLLED STUDY; CROSS REACTION; CYTOTOXICITY; ELECTROSTIMULATION; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HUMORAL IMMUNITY; IMMUNIZATION; MOUSE; NONHUMAN; ONCOGENE NEU; PRIORITY JOURNAL; SPLEEN CELL; T LYMPHOCYTE; TRANSGENIC MOUSE; TUMOR GROWTH; VACCINATION;

ADENOVIRIDAE; ANIMALS; ANTIBODIES, HETEROPHILE; CANCER VACCINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES, B-LYMPHOCYTE; EPITOPES, T-LYMPHOCYTE; FEMALE; FLOW CYTOMETRY; GENES, ERBB-2; GENETIC VECTORS; IMMUNODOMINANT EPITOPES; INTERFERON TYPE II; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, INBRED STRAINS; MICE, TRANSGENIC; PLASMIDS; RATS; RECEPTOR, ERBB-2; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, DNA;

EID: 8644282802     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20536     Document Type: Article

References (31)

1. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlieriger K, Liebman MN, Rubin SC, Coukos G. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003;348:203-13.
2. Knutson KL, Schiffman K, Disis ML. Immunization with a HER-2/neu helper peptide vaccine generates HER- 2/neu CD8 T-cell immunity in cancer patients. J Clin Invest 2001;107:477-84.
3. Hodge JW, Grosenbach DW, Aarts WM, Poole DJ, Schlom J. Vaccine therapy of established tumors in the absence of autoimmunity. Clin Cancer Res 2003;9:1837-49.
4. Dupuis M, Denis-Mize K, Woo C, Goldbeck C, Selby MJ, Chen M, Otten GR, Ulmer JB, Donnelly JJ, Ott G, McDonald DM. Distribution of DNA vaccines determines their immunogenicity after intramuscular injection in mice. J Immunol 2000;165:2850-8.
5. Aarts WM, Schlom J, Hodge JW. Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity. Cancer Res 2002;62:5770-7.
6. Hung MC, Lau YK. Basic science of HER-2/neu: a review. Semin Oncol 1999;26(4 Suppl 12):51-9.
7. Disis ML, Schiffman K. Cancer vaccines targeting the HER2/neu oncogenic protein. Semin Oncol 2001;28(6 Suppl 18):12-20.
8. Wei YQ. Immunotherapy of tumors with vaccines based on xenogeneic homologous molecules. Anticancer Drugs 2002;13:229-35.
9. Hawkins WG, Gold JS, Dyall R, Wolchok JD, Hoos A, Bowne WB, Srinivasan R, Houghton AN, Lewis JJ. Immunization with DNA coding for gp100 results in CD4 T-cell independent antitumor immunity. Surgery 2000;128:273-80.
10. Lucchini F, Sacco MG, Hu N, Villa A, Brown J, Cesano L, Mangiarini L, Rindi G, Kindl S, Sessa F, et al. Early and multifocal tumors in breast, salivary, harderian and epididymal tissues developed in MMTY-Neu transgenic mice. Cancer Lett 1992;64:203-9.
11. Di Fiore PP, Pierce JH, Kraus MH, Segatto O, King CR, Aaronson SA. erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science 1987;237:178-82.
12. Nanni P, Pupa SM, Nicoletti G, De Giovanni C, Landuzzi L, Rossi I, Astolfi A, Ricci C, De Vecchi R, Invernizzi AM, Di Carlo E, Musiani P, et al. p185(neu) protein is required for tumor and anchorage-independent growth, not for cell proliferation of transgenic mammary carcinoma. Int J Cancer 2000;87:186-94.
13. Tzahar E, Pinkas-Kramarski R, Moyer JD, Klapper LN, Alroy I, Levkowitz G, Shelly M, Henis S, Eisenstein M, Ratzkin BJ, Sela M, Andrews GC, et al. Bivalence of EGF-like ligands drives the ErbB signaling network. EMBO J 1997;16:4938-50.
14. Kozak M. An analysis of 5′-noncoding sequences from 699 vertebrate messenger RNAs. Nucl Acids Res 1987;15:8125-48.
15. Kozak M. At least six nucleotides preceding the AUG initiator codon enhance translation in mammalian cells. J Mol Biol 1987;196:947-50.
16. Montgomery DL, Shiver JW, Leander KR, Perry HC, Friedman A, Martinez D, Ulmer JB, Donnelly JJ, Liu MA. Heterologous and homologous protection against influenza A by DNA vaccination: optimization of DNA vectors. DNA Cell Biol 1993;12:777-83.
17. Rovero S, Amici A, Carlo ED, Bei R, Nanni P, Quaglino E, Porcedda P, Boggio K, Smorlesi A, Lollini PL, Landuzzi L, Colombo MP, et al. DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice. J Immunol 2000;165:5133-42.
18. Youil R, Toner TJ, Su Q, Casimiro D, Shiver JW, Chen L, Bett AJ, Rogers BM, Burden EC, Tang A, Chen M, Emini EA, et al. Comparative analysis of the effects of packaging signal, transgene orientation, promoters, polyadenylation signals, and E3 region on growth properties of first-generation adenoviruses. Hum Gene Ther 2003;14:1017-34.
19. Fallaux FJ, Bout A, van der Velde I, van den Wollenberg DJ, Hehir KM, Keegan J, Auger C, Cramer SJ, van Ormondt H, van der Eb AJ, Valerio D, Hoeben RC. New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. Hum Gene Ther 1998;9:1909-17.
20. Ishibashi M, Maizel JV Jr. The polypeptides of adenovirus: V, young virions, structural intermediate between top components and aged virions. Virology 1974;57:409-24.
21. Chakrabarti S, Brechling K, Moss B. Vaccinia virus expression vector: coexpression of beta-galactosidase provides visual screening of recombinant virus plaques. Mol Cell Biol 1985;5:3403-9.
22. Fu TM, Mylin LM, Schell TD, Bacik I, Russ G, Yewdell JW, Bennink JR, Tevethia SS. An endoplasmic reticulum-targeting signal sequence enhances the immunogenicity of an immunorecessive simian virus 40 large T antigen cytotoxic T-lymphocyte epitope. J Virol 1998;72:1469-81.
23. Boggio K, Nicoletti G, Di Carlo E, Cavallo F, Landuzzi L, Melani C, Giovarelli M, Rossi I, Nanni P, De Giovanni C, Bouchard P, Wolf S, et al. Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic mice. J Exp Med 1998;188:589-96.
24. Rizzuto G, Cappelletti M, Maione D, Savino R, Lazzaro D, Costa P, Mathiesen I, Cortese R, Ciliberto G, Laufer R, La Monica N, Fattori E. Efficient and regulated erythropoietin production by naked DNA injection and muscle electroporation. Proc Natl Acad Sci USA 1999;96:6417-22.
25. + T cells using an ELISPOT assay. J Immunol Methods 1995;181:45-54.
26. Zucchelli S, Capone S, Fattori E, Folgori A, Di Marco A, Casimiro D, Simon AJ, Laufer R, La Monica N, Cortese R, Nicosia A. Enhancing B- and T-cell immune response to a hepatitis C virus E2 DNA vaccine by intramuscular electrical gene transfer. J Virol 2000;74:11598-607.
27. Nagata Y, Furugen R, Hiasa A, Ikeda H, Ohta N, Furukawa K, Nakamura H, Kanematsu T, Shiku H. Peptides derived from a wildtype murine proto-oncogene c-erbB-2/HER2/neu can induce CTL and tumor suppression in syngeneic hosts. J Immunol 1997;159:1336-43.
28. Sioud M, Sorensen D. Generation of an effective anti-tumor immunity after immunization with xenogeneic antigens. Eur J Immunol 2003;33:38-45.
29. Casimiro DR, Chen L, Fu TM, Evans RK, Caulfield MJ, Davies ME, Tang A, Chen M, Huang L, Harris V, Freed DC, Wilson KA, et al. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J Virol 2003;77:6305-13.
30. Matsui M, Moriya O, Akatsuka T. Enhanced induction of hepatitis C virus-specific cytotoxic T lymphocytes and protective efficacy in mice by DNA vaccination followed by adenovirus boosting in combination with the interleukin-12 expression plasmid. Vaccine 2003;21:1629-39.
31. Wei YQHM, Yang L, Zhao X, Tian L, Lu Y, Shu JM, Lu CJ, Niu T, Kang BMY, Liu F, Wen YJ, Lei S, et al. Immunogene therapy of tumors with vaccine based on Xenopus homologous vascular endothelial growth factor as a model antigen. Proc Natl Acad Sci USA 2001;98:11545-50.